

RESEARCH MONOGRAPH . COMPOUND PROFILE

L-Carnitine

A conditionally essential nutrient and FDA-approved pharmaceutical (levocarnitine) that mediates the translocation of long-chain fatty acyl groups across the inner mitochondrial membrane, with clinical applications spanning primary and secondary carnitine deficiency, cardiovascular secondary prevention, hemodialysis support, exercise performance, male reproductive health, and neuroprotection.

DOCUMENT	KDC-MN-1516
ISSUED	2026-05-15
REVISION	1.0
AUTHOR	Kodiac bioLabs Research
COMPOUND CLASS	Endogenous quaternary ammonium compound functioning as an obligate cofactor in mitochondrial long-chain fatty acid beta-oxidation via the carnitine palmitoyltransferase shuttle system

ABSTRACT

L-Carnitine (levocarnitine) is a naturally occurring, water-soluble quaternary ammonium compound biosynthesized from the amino acids lysine and methionine in liver, kidney, and brain, and obtained exogenously from dietary sources (principally red meat and dairy products) and from pharmaceutical or nutraceutical supplementation. The compound is an obligate cofactor for the carnitine palmitoyltransferase (CPT) shuttle system, the sole mechanism by which long-chain fatty acyl-coenzyme A esters cross the inner mitochondrial membrane to undergo beta-oxidation. In the absence of adequate carnitine, mitochondrial long-chain fatty acid oxidation is impaired, producing the metabolic phenotype of primary systemic carnitine deficiency: hypoketotic hypoglycemia, cardiomyopathy, skeletal myopathy, and hepatic encephalopathy. The compound was first isolated from vertebrate muscle extract by Gulewitsch and Krimberg in 1905, structurally characterized as beta-hydroxy-gamma-trimethylaminobutyric acid by Tomita and Sendju in 1927, identified as the insect growth factor vitamin BT by Fraenkel and colleagues in the 1950s, and functionally linked to fatty acid oxidation by Fritz in 1955. Its obligate role in mitochondrial bioenergetics was established through the subsequent characterization of the CPT I, carnitine-acylcarnitine translocase (CACT), and CPT II enzyme system by McGarry, Foster, Ramsay, and colleagues in the 1970s and 1980s.

L-Carnitine is approved by the United States Food and Drug Administration as levocarnitine (Carnitor, Leadiant Biosciences) for the treatment of primary systemic carnitine deficiency and for

the prevention and treatment of carnitine deficiency in patients with end-stage renal disease undergoing maintenance hemodialysis. Pharmacokinetics are characterized by carrier-mediated intestinal absorption via the organic cation/carnitine transporter OCTN2 (SLC22A5), with oral bioavailability of 54 to 87 percent from dietary sources but only 14 to 18 percent from high-dose oral supplements owing to saturation of active transport. Renal handling is dominated by efficient tubular reabsorption (90 to 99 percent of filtered load) via OCTN2 at physiological plasma concentrations, with saturable reabsorption kinetics producing rapid urinary clearance of supraphysiological doses. Plasma elimination half-life is approximately 2 to 6 hours for exogenous doses; the endogenous total body pool (approximately 20 to 25 grams in a 70-kilogram adult) turns over slowly with an estimated whole-body half-life of 40 to 100 hours.

Clinical evidence for supplemental L-carnitine spans multiple therapeutic domains. In cardiovascular secondary prevention, a 2013 meta-analysis of 13 controlled trials (N = 3,629) by DiNicolantonio et al. in Mayo Clinic Proceedings reported a 27 percent reduction in all-cause mortality (OR 0.73, 95% CI 0.54 to 0.99), a 65 percent reduction in ventricular arrhythmias, and a 40 percent reduction in angina development in patients following acute myocardial infarction. In chronic heart failure, a 2017 meta-analysis of 17 trials (N = 1,625) reported significant improvements in left ventricular ejection fraction (+4.14%), stroke volume (+8.21 mL), and cardiac output (+0.88 L/min). In hemodialysis populations, Cochrane and systematic reviews have reported potential benefits for anemia, C-reactive protein reduction, and intradialytic hypotension, though evidence quality remains low to moderate. In exercise physiology, systematic reviews report benefits of 1 to 4 grams daily on VO₂max, peak power output, and

lactate reduction, with effect sizes dependent on dosing duration and exercise modality. In male reproductive health, meta-analyses report significant improvements in sperm motility and morphology with 1 to 3 grams daily for 3 to 6 months, though pregnancy rate improvements have not been consistently demonstrated. Acetyl-L-carnitine, a physiological ester derivative, has demonstrated efficacy in randomized controlled trials for diabetic peripheral neuropathy, with significant pain reduction and nerve fiber regeneration.

A safety consideration of growing importance is the gut microbial conversion of L-carnitine to trimethylamine (TMA), which undergoes hepatic oxidation by flavin-containing monooxygenase 3 (FMO3) to trimethylamine N-oxide (TMAO), a metabolite epidemiologically associated with increased atherosclerotic cardiovascular disease risk. The TMAO pathway is diet-dependent and microbiome-dependent, with omnivorous individuals producing substantially more TMAO from carnitine challenge than vegetarians or vegans. This monograph reviews the chemistry, biosynthesis, and transport of L-carnitine; the carnitine shuttle mechanism in molecular detail; the comprehensive pharmacokinetic record; the clinical evidence base across all studied indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal including the TMAO pathway; and a comparative assessment of five mitochondrial bioenergetic support compounds against L-carnitine on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Levocarnitine.

Common names: L-Carnitine, levocarnitine, L-(-)-carnitine, vitamin BT (historical, now deprecated as a vitamin designation in humans).

Marketed names: Carnitor (Leadiant Biosciences, formerly Sigma-Tau Pharmaceuticals; United States), Carnitor SF (sugar-free oral solution, United States), various generic levocarnitine preparations in multiple jurisdictions. Nutraceutical-grade L-carnitine is marketed under numerous brand names globally.

Chemical Abstracts Service registry numbers: 541-15-1 (L-carnitine, free zwitterionic form), 6645-46-1 (L-carnitine hydrochloride), 5765-44-6 (L-carnitine L-tartrate). The free zwitterionic form is the endogenous species and the pharmacopoeial reference; the hydrochloride and tartrate salts are the principal supplemental and pharmaceutical forms.

International Union of Pure and Applied Chemistry name: (R)-3-hydroxy-4-(trimethylammonio)butanoate. The compound is a betaine (inner salt) of a quaternary ammonium hydroxide and a carboxylic acid, existing as a zwitterion at physiological pH. The (R)-configuration at carbon 3 is the biologically active stereoisomer; the (S)-enantiomer (D-carnitine) is biologically inactive and potentially inhibitory to endogenous L-carnitine transport.

Other registry identifiers: PubChem CID 10917; ChEBI 17126; DrugBank DB00583; KEGG C00318; HMDB HMDB0000062.

1.2 Structural class and chemistry

L-Carnitine is a small, water-soluble quaternary ammonium compound of the betaine structural class. It is not an amino acid in the strict biochemical sense (it lacks an alpha-amino group), though it is frequently categorized among the amino acid-derived compounds owing to its biosynthesis from protein-bound lysine and methionine residues [1, 2].

Molecular formula: C₇H₁₅NO₃.

Exact mass: 161.1052 g/mol (monoisotopic).

Molecular weight: 161.20 g/mol (free zwitterion); 197.66 g/mol (hydrochloride salt); 311.33 g/mol (L-tartrate salt, anhydrous).

Physical properties: White crystalline hygroscopic powder or transparent crystals. Freely soluble in water (greater than 2,500 g/L at 20 degrees Celsius), soluble in methanol and ethanol, sparingly soluble in acetone and ethyl acetate, practically insoluble in chloroform and diethyl ether. Melting point approximately 197 to 200 degrees Celsius with decomposition. The compound is stable in aqueous solution at pH 3 to 8; degradation accelerates at extremes of pH and at temperatures above 40 degrees Celsius. Optical rotation [α]_{D20} is approximately -31 to -32 degrees (c = 1, H₂O) for the pure (R)-enantiomer.

Stereochemistry: L-Carnitine contains a single stereocenter at carbon 3 with (R)-configuration. The biologically active form is exclusively the (R)-enantiomer. The (S)-enantiomer (D-carnitine) is not a physiological substrate for the carnitine palmitoyltransferase system and competitively inhibits OCTN2-mediated transport of L-carnitine; racemic DL-carnitine is therefore contraindicated in supplementation and is not used in pharmaceutical or research-grade preparations [3]. All commercial and pharmaceutical L-carnitine is supplied as the pure (R)-enantiomer with enantiomeric excess greater than 99 percent.

1.3 Biosynthesis

L-Carnitine is biosynthesized endogenously in humans from the essential amino acids lysine and methionine through a four-step enzymatic pathway [1, 2, 4]. The pathway begins with protein-bound lysine residues that have been trimethylated at the epsilon-amino group by specific protein-lysine methyltransferases using S-adenosylmethionine as the methyl donor. Following proteolytic release of epsilon-N-trimethyllysine (TML), the free TML is converted to L-carnitine through four sequential enzymatic reactions:

1. Epsilon-N-trimethyllysine is hydroxylated at the 3-position by trimethyllysine dioxygenase (TMLD, also termed trimethyllysine hydroxylase), a 2-oxoglutarate-dependent, iron(II)-containing dioxygenase requiring molecular oxygen and ascorbate. This reaction produces 3-hydroxy-6-N-trimethyllysine (HTML).

2. HTML is cleaved by a specific aldolase (HTML aldolase, also termed serine hydroxymethyltransferase in some organisms) to yield 4-trimethylaminobutyraldehyde (TMABA) and glycine. This step requires pyridoxal 5'-phosphate as cofactor.
3. TMABA is oxidized to gamma-butyrobetaine (4-N-trimethylaminobutyrate) by 4-trimethylaminobutyraldehyde dehydrogenase (TMABA-DH), an NAD-dependent aldehyde dehydrogenase.
4. Gamma-butyrobetaine is hydroxylated at the 3-position by gamma-butyrobetaine dioxygenase (BBD, also termed gamma-butyrobetaine hydroxylase), a second 2-oxoglutarate-dependent, iron(II)-containing dioxygenase requiring molecular oxygen and ascorbate, to yield L-carnitine.

The final hydroxylation step (BBD) is tissue-restricted in humans, occurring predominantly in liver, kidney, and brain. Skeletal muscle and cardiac muscle, the tissues with the highest carnitine concentrations, do not express BBD and are therefore entirely dependent on plasma uptake for their carnitine supply. The biosynthetic cofactor requirements (ascorbate, iron, pyridoxal 5'-phosphate, 2-oxoglutarate) establish a dependence on adequate vitamin C, vitamin B6, and iron status for endogenous carnitine production [4].

Endogenous biosynthesis produces approximately 1.2 micromoles per kilogram body weight per day (approximately 11 to 16 mg/day in a 70-kilogram adult). Dietary intake from a mixed omnivorous diet contributes approximately 20 to 200 mg/day, with red meat being the principal source (approximately 60 to 160 mg per 100 grams of beef, lamb, or venison). Vegetarian and vegan diets provide substantially less (approximately 1 to 10 mg/day), though endogenous biosynthesis compensates, and frank carnitine deficiency is rare in otherwise healthy vegetarians [5].

2. Abstract

L-Carnitine (levocarnitine) is the sole physiological carrier for the translocation of long-chain fatty acyl groups (carbon chain length 14 to 20) across the inner mitochondrial membrane, a transport step that is rate-limiting for mitochondrial beta-oxidation and, consequently, for the oxidative energy metabolism of cardiac muscle, skeletal muscle, hepatocytes, and renal tubular epithelial cells [1, 6]. The compound operates through the carnitine palmitoyltransferase shuttle: long-chain fatty acyl-CoA is transesterified to L-carnitine by carnitine palmitoyltransferase I (CPT I) on the outer mitochondrial membrane, the resulting acylcarnitine is translocated across the inner membrane by carnitine-acylcarnitine translocase (CACT), and the acyl group is transferred back to intramitochondrial coenzyme A by carnitine palmitoyltransferase II (CPT II) on the matrix face, regenerating free L-carnitine for export [6, 7].

Beyond its canonical transport function, L-carnitine serves as a buffer of the mitochondrial acyl-CoA/free CoA ratio, a modulator of the pyruvate dehydrogenase complex (by sequestering excess acetyl groups as acetylcarnitine, thereby relieving product inhibition and favoring glucose oxidation), and a scavenger of potentially toxic acyl groups generated during branched-chain amino acid catabolism, organic acidemias, valproic acid therapy, and other metabolic stresses [8, 9]. The acetylcarnitine/free carnitine ratio in plasma and tissue is a recognized biomarker of mitochondrial metabolic flexibility and substrate utilization status.

L-Carnitine is approved as a pharmaceutical (Carnitor, levocarnitine) by the United States Food and Drug Administration for the treatment of primary systemic carnitine deficiency and for the management of carnitine depletion in end-stage renal disease patients undergoing maintenance hemodialysis [10]. As a dietary supplement and nutraceutical, L-carnitine and its ester derivatives (acetyl-L-carnitine, propionyl-L-carnitine, L-carnitine L-tartrate, glycine propionyl-L-carnitine) are widely used for cardiovascular support, exercise performance enhancement, male fertility optimization, neuroprotection, and general metabolic health, with varying levels of clinical evidence supporting each application.

The principal safety consideration for chronic high-dose L-carnitine supplementation is the gut microbial metabolism of unabsorbed carnitine to trimethylamine (TMA), subsequently oxidized by hepatic flavin-containing monooxygenase 3 (FMO3) to trimethylamine N-oxide (TMAO), a proatherogenic metabolite associated with increased cardiovascular risk in epidemiological studies [11, 12]. This pathway introduces a paradox in which a compound with demonstrated cardiovascular benefit in post-myocardial infarction secondary prevention may simultaneously promote atherogenic metabolite production through a microbiome-dependent mechanism. The balance of benefit and risk is dose-dependent, duration-dependent, and microbiome-dependent, and is a subject of active investigation.

3. Discovery and Development History

3.1 Isolation and structural characterization

L-Carnitine was first isolated from vertebrate skeletal muscle extract by the Russian biochemists Vladimir Gulevich (Gulewitsch) and Robert Krimberg at the University of Moscow in 1905, who named the compound "carnitine" from the Latin *carnis* (flesh) [1, 13]. The isolation yielded a nitrogenous base that resisted further characterization with the analytical methods available at the time. In 1927, Tomita and Sendju established the chemical structure as beta-hydroxy-gamma-trimethylaminobutyric acid (3-hydroxy-4-trimethylaminobutyrate) [14]. The absolute stereochemical configuration was subsequently determined as (R) by correlation with (R)-malic acid.

3.2 Vitamin BT and the insect growth factor

In the late 1940s, Gottfried Fraenkel at the University of Illinois, investigating nutritional requirements of the mealworm *Tenebrio molitor*, identified a growth factor present in yeast and liver extract that was required for normal development of seven species of the Tenebrionidae family [15]. Fraenkel designated this factor vitamin BT (T for *Tenebrio*). The factor was extremely hygroscopic and difficult to crystallize, delaying its identification. In 1952, Carter and colleagues at the University of Illinois completed the purification and identification of vitamin BT as L-carnitine [16]. The vitamin designation was subsequently deprecated for mammals and humans, as endogenous biosynthesis was demonstrated to be sufficient under normal physiological conditions, though the designation "conditionally essential nutrient" persists in the nutritional literature for conditions of increased demand or impaired biosynthesis.

3.3 Functional role in fatty acid oxidation

The functional link between carnitine and fatty acid oxidation was established by Irving Fritz at the University of Michigan in 1955, who demonstrated that carnitine stimulated the oxidation of long-chain fatty acids by isolated muscle mitochondria [17]. Fritz proposed that carnitine facilitated the entry of fatty acids into the mito-

chondrial matrix, a hypothesis confirmed by the subsequent characterization of the carnitine palmitoyltransferase system. The enzymatic basis of the carnitine shuttle was established through the work of McGarry and Foster at the University of Texas Southwestern Medical Center and Ramsay and colleagues at other institutions in the 1970s and 1980s, culminating in the complete description of the CPT I, CACT, and CPT II enzyme system and the regulatory role of malonyl-CoA as the physiological inhibitor of CPT I [6, 7, 18].

3.4 Clinical recognition of carnitine deficiency

Primary systemic carnitine deficiency was first described clinically by Engel and Angelini in 1973 as a myopathic syndrome associated with lipid storage in muscle fibers and very low plasma and tissue carnitine concentrations [19]. The genetic basis was identified as loss-of-function mutations in the SLC22A5 gene encoding the high-affinity carnitine transporter OCTN2, with autosomal recessive inheritance [20]. The condition, though rare (estimated prevalence approximately 1 in 40,000 to 1 in 120,000 in most populations, with higher frequencies in the Faroe Islands and certain East Asian populations), established carnitine as an essential metabolic co-factor and provided the basis for pharmaceutical development.

3.5 Pharmaceutical development

Sigma-Tau Pharmaceuticals (now Leadiant Biosciences) developed levocarnitine as Carnitor and received FDA approval for the oral tablet formulation in 1986 for primary systemic carnitine deficiency. The intravenous formulation was subsequently approved for the prevention and treatment of carnitine deficiency in end-stage renal disease patients on dialysis, based on the recognition that hemodialysis removes carnitine (molecular weight 161 daltons, below the dialysis membrane cut-off) and that chronic dialysis patients develop progressive carnitine depletion with clinical consequences including cardiomyopathy, skeletal myopathy, anemia resistant to erythropoietin, and intradialytic hypotension [10, 21].

3.6 Expansion of research and supplemental applications

Beginning in the 1990s, the research and supplemental application of L-carnitine expanded substantially beyond the treatment of frank deficiency states. Clinical investigation proceeded in cardiovascular secondary prevention (post-myocardial infarction), chronic heart failure, exercise performance, male infertility, diabetic

neuropathy (principally with the acetyl-L-carnitine ester), cognitive decline, and cancer-related fatigue. The 2013 meta-analysis by DiNicolantonio et al. in Mayo Clinic Proceedings, demonstrating a 27 percent reduction in all-cause mortality in post-myocardial infarction patients, represented the highest-impact clinical finding in the supplemental application literature [22]. Simultaneously, the 2013 Koeth et al. report in Nature Medicine, demonstrating the gut microbial conversion of dietary L-carnitine to the proatherogenic metabolite TMAO, introduced a mechanistic safety concern that has shaped the subsequent research trajectory [11].

4. Mechanism of Action

4.1 The carnitine palmitoyltransferase shuttle

The principal molecular function of L-carnitine is the facilitation of long-chain fatty acid entry into the mitochondrial matrix for beta-oxidation. Long-chain fatty acids (carbon chain length 14 to 20) activated to their coenzyme A thioesters in the cytosol cannot cross the inner mitochondrial membrane directly; the membrane is impermeable to CoA and to long-chain acyl-CoA. The carnitine shuttle provides the sole physiological mechanism for this translocation and consists of three enzymatic components [6, 7]:

Carnitine palmitoyltransferase I (CPT I): Located on the outer mitochondrial membrane (cytosolic face), CPT I catalyzes the reversible transesterification of long-chain acyl-CoA with L-carnitine to form long-chain acylcarnitine and free CoA. Three tissue-specific isoforms exist: CPT Ia (liver), CPT Ib (muscle, heart), and CPT Ic (brain; function debated). CPT I is the rate-limiting enzyme of the shuttle and is subject to allosteric inhibition by malonyl-CoA, the product of acetyl-CoA carboxylase and the first committed intermediate of de novo fatty acid synthesis. This malonyl-CoA inhibition provides the principal regulatory integration between fatty acid oxidation and fatty acid synthesis: when carbohydrate availability is high and insulin signaling is active, malonyl-CoA concentrations rise and suppress CPT I, diverting fatty acids from oxidation to storage; when carbohydrate availability is low and glucagon or catecholamine signaling predominates, malonyl-CoA concentrations fall and CPT I is derepressed, permitting fatty acid oxidation to supply acetyl-CoA to the tricarboxylic acid cycle and ATP to the electron transport chain [18].

Carnitine-acylcarnitine translocase (CACT): Located in the inner mitochondrial membrane, CACT mediates the exchange of acylcarnitine (inward) for free carnitine (outward) across the inner membrane. CACT is encoded by the SLC25A20 gene and functions as a strict antiporter; deficiency produces a severe neonatal metabolic crisis with hypoketotic hypoglycemia and cardiac arrhythmia [23].

Carnitine palmitoyltransferase II (CPT II): Located on the matrix face of the inner mitochondrial membrane, CPT II catalyzes the reverse transesterification, regenerating long-chain acyl-CoA (now within the mitochondrial matrix and available for beta-oxidation) and free L-carnitine (which is exported back to the cytosol via CACT to complete the shuttle cycle). CPT II deficiency is the most common inherited disorder of long-chain fatty acid oxidation in adults, presenting as exercise-induced rhabdomyolysis [24].

4.2 Acyl-CoA/CoA buffering and metabolic flexibility

Beyond the canonical transport function, L-carnitine serves as a buffer of the intramitochondrial acyl-CoA/free CoA ratio through the reversible formation of short-chain and medium-chain acylcarnitines [8, 9]. This buffering function has several metabolic consequences:

Carnitine acetyltransferase (CrAT), located in the mitochondrial matrix, catalyzes the reversible transfer of acetyl groups between acetyl-CoA and L-carnitine. When mitochondrial acetyl-CoA accumulates in excess of tricarboxylic acid cycle capacity (as during high rates of fatty acid oxidation, branched-chain amino acid catabolism, or pyruvate dehydrogenase flux), CrAT transfers acetyl groups to carnitine, forming acetylcarnitine. This acetylcarnitine can be exported from the mitochondrion and from the cell, serving as a "sink" for excess acetyl groups and regenerating free CoA for continued metabolic flux. The process is particularly important in exercising skeletal muscle, where CrAT-mediated acetyl buffering preserves metabolic flexibility and permits the transition between fatty acid and glucose oxidation [25].

The CrAT-mediated buffering also relieves product inhibition of the pyruvate dehydrogenase complex (PDH). Accumulated acetyl-CoA inhibits PDH and favors continued fatty acid oxidation at the expense of glucose oxidation (metabolic inflexibility, characteristic of insulin resistance and type 2 diabetes). By sequestering excess acetyl groups as acetylcarnitine, carnitine indirectly promotes PDH activity and glucose oxidation, contributing to improved metabolic flexibility [25, 26].

4.3 Detoxification of aberrant acyl groups

L-Carnitine functions as a scavenger of potentially toxic acyl-CoA esters generated during organic acidemias, valproic acid therapy, and other conditions that produce accumulations of nonphysiological or excess acyl groups [9]. By accepting these acyl groups and forming water-soluble acylcarnitines that can be excreted renally, carnitine prevents CoA sequestration (which would otherwise impair multiple CoA-dependent metabolic pathways) and facilitates urinary elimination of the offending acyl moieties. This detoxification function is the basis for the FDA-approved indication of levocarnitine in organic acidemias and for the clinical use of L-carnitine in the management of valproic acid-induced hyperammonemia and hepatotoxicity [27].

4.4 Membrane stabilization and antioxidant activity

L-Carnitine and its acylcarnitine derivatives have been reported to stabilize cell membranes and to exert indirect antioxidant effects through modulation of the glutathione system, reduction of lipid peroxidation, and upregulation of antioxidant enzyme expression [28]. These effects have been demonstrated primarily in vitro and in animal models. The antioxidant activity is secondary to the metabolic functions and is not mediated by direct radical scavenging (L-carnitine lacks the structural features of classical chain-breaking antioxidants) but rather by metabolic normalization that reduces mitochondrial reactive oxygen species production.

4.5 OCTN2-mediated cellular uptake

The tissue distribution of L-carnitine is maintained against a steep concentration gradient: skeletal and cardiac muscle concentrations (approximately 3,000 to 5,000 micromoles per liter of intracellular water) exceed plasma concentrations (approximately 40 to 60 micromoles per liter) by approximately 50- to 100-fold [20]. This gradient is maintained by the high-affinity sodium-dependent organic cation/carnitine transporter OCTN2 (SLC22A5), which is expressed on the plasma membrane of cardiac myocytes, skeletal myocytes, renal tubular epithelial cells, intestinal epithelial cells, placental trophoblasts, and other tissues. OCTN2 has a K_m for L-carnitine of approximately 4 to 5 micromoles per liter, consistent with efficient uptake at physiological plasma concentrations. Loss-of-function mutations in SLC22A5 produce primary systemic carnitine deficiency [20].

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Oral absorption of L-carnitine is mediated by both active (OCTN2-dependent) and passive transport mechanisms in the small intestine [29, 30]. The relative contribution of each mechanism is dose-dependent:

At dietary intake levels (approximately 2 to 12 micromoles per meal, corresponding to 0.3 to 2 mg), absorption is predominantly OCTN2-mediated and highly efficient, with bioavailability of 54 to 87 percent. At supplemental doses (0.5 to 6 grams per dose), the OCTN2 carrier is saturated and absorption becomes predominantly passive; bioavailability falls to 14 to 18 percent of the administered dose, with the unabsorbed fraction available for metabolism by colonic microbiota [29].

Time to peak plasma concentration after oral supplemental doses of 1 to 6 grams is approximately 3 to 4 hours. Peak plasma concentrations after a single 2-gram oral dose in healthy adults are approximately 80 to 100 micromoles per liter (approximately 2-fold above baseline fasting concentrations of 40 to 60 micromoles per liter) [29, 30].

Acetyl-L-carnitine is absorbed at least partially without hydrolysis, as demonstrated by the 43 percent increase in circulating acetylcarnitine concentrations following 2 grams per day of oral acetyl-L-carnitine supplementation [30]. The intact absorption permits direct delivery of the acetylated form to tissues.

5.2 Distribution

Total body carnitine stores in a 70-kilogram adult are approximately 20 to 25 grams, of which greater than 95 percent resides in skeletal and cardiac muscle. Plasma total carnitine concentrations in healthy adults range from approximately 40 to 60 micromoles per liter, of which approximately 75 to 80 percent is free carnitine and 20 to 25 percent is acylcarnitine (predominantly acetylcarnitine and propionylcarnitine) [5, 30].

Volume of distribution for exogenous L-carnitine is approximately 0.2 to 0.3 liters per kilogram (suggesting distribution predominantly within the extracellular fluid compartment on acute dosing, with slower equilibration into the large intracellular muscle pool). The compound is not significantly bound to plasma proteins. L-Carnitine crosses the blood-brain barrier, though central nervous system concentrations are lower than those in skeletal and cardiac muscle; acetyl-L-carnitine has been reported to cross the blood-brain barrier more efficiently than free L-carnitine [31].

5.3 Metabolism

L-Carnitine undergoes limited hepatic metabolism. The principal metabolic pathways are:

Reversible esterification: L-Carnitine is reversibly esterified with various acyl groups (acetyl, propionyl, palmitoyl, and others) by the carnitine acyltransferase family of enzymes. These acylcarnitines are normal physiological intermediates and are not degradation products; they are interconvertible with free carnitine and acyl-CoA.

Gut microbial metabolism: Unabsorbed oral L-carnitine (the 80 to 86 percent of supplemental doses not absorbed in the small intestine) undergoes metabolism by colonic microbiota to gamma-butyrobetaine and to trimethylamine (TMA). TMA is absorbed from the colon and oxidized in the liver by flavin-containing monooxygenase 3 (FMO3) to trimethylamine N-oxide (TMAO) [11, 12]. This gut microbial pathway is the principal source of the TMAO-mediated cardiovascular risk concern associated with chronic high-dose L-carnitine supplementation.

Endogenous turnover: The endogenous total body carnitine pool turns over slowly, with an estimated whole-body half-life of 40 to 100 hours under steady-state conditions [30].

5.4 Elimination

Renal excretion is the dominant elimination pathway for both free carnitine and acylcarnitines. At physiological plasma concentrations, renal tubular reabsorption of filtered carnitine via OCTN2 is highly efficient (90 to 99 percent of filtered load; renal clearance approximately 1 to 3 mL/min) [29, 30]. As plasma carnitine concentrations rise above the physiological range (as after high-dose oral or intravenous

administration), OCTN2 reabsorption saturates, renal clearance increases markedly, and excess carnitine is rapidly excreted in urine. This saturable renal reabsorption is the principal reason that supraphysiological oral or intravenous doses produce only transient elevations in plasma concentration, with rapid return to baseline.

Plasma elimination half-life for exogenous L-carnitine is approximately 2 to 6 hours in individuals with normal renal function, reflecting the rapid renal clearance of supraphysiological concentrations. In end-stage renal disease, renal clearance is absent, and hemodialysis removes carnitine (molecular weight 161, freely dialyzable); the combination of absent renal conservation and dialytic loss produces the progressive carnitine depletion that motivates pharmaceutical supplementation in this population [21].

5.5 Routes of administration

Oral: The principal route for both pharmaceutical and supplemental applications. Pharmaceutical levocarnitine (Carnitor) is available as 330 mg tablets, oral solution (100 mg/mL), and sugar-free oral solution. Supplemental L-carnitine is available as free base, hydrochloride, L-tartrate, fumarate, and various ester derivatives (acetyl-L-carnitine, propionyl-L-carnitine, glycine propionyl-L-carnitine). Typical supplemental doses range from 500 mg to 3,000 mg per day in divided doses.

Intravenous: Pharmaceutical levocarnitine injection (Carnitor, 200 mg/mL, 5 mL vials containing 1 gram) is approved for intravenous administration in hemodialysis patients, typically administered as a 10 to 20 mg/kg bolus at the end of each dialysis session. The intravenous route produces immediate peak plasma concentrations and is used in acute carnitine deficiency crises and in the dialysis setting.

Intramuscular: Studied in some clinical research protocols but not a registered route.

5.6 Special populations

Pediatric: Neonates and infants have lower endogenous carnitine biosynthesis and lower tissue stores than adults, particularly premature infants. Breast milk and infant formula provide carnitine; soy-based formulas may require carnitine fortifica-

tion. Pediatric dosing of pharmaceutical levocarnitine for primary carnitine deficiency is 50 to 100 mg/kg/day in divided doses, with a maximum of 3 grams per day [10].

Geriatric: Plasma carnitine concentrations tend to decline with age, and tissue carnitine depletion may contribute to age-related sarcopenia and metabolic inflexibility. Acetyl-L-carnitine has been studied for age-related cognitive decline and fatigue [32].

Pregnancy and lactation: L-Carnitine is present in breast milk and crosses the placenta. Pregnancy is associated with declining plasma carnitine concentrations, attributed to increased fetal demand and altered renal handling. Supplementation during pregnancy has been studied in small trials without demonstrated harm; large-scale safety data are limited.

Renal impairment: End-stage renal disease patients on hemodialysis develop carnitine depletion. The FDA-approved indication for levocarnitine injection addresses this population specifically [21].

Vegetarians and vegans: Lower dietary carnitine intake is compensated by increased endogenous biosynthesis and enhanced renal reabsorption efficiency, though plasma carnitine concentrations are modestly lower (approximately 10 to 20 percent) than in omnivores [5].

6. Clinical Evidence Base

6.1 Primary systemic carnitine deficiency

Primary systemic carnitine deficiency (OMIM 212140) is caused by homozygous or compound heterozygous loss-of-function mutations in SLC22A5 (encoding OCTN2). The clinical presentation includes recurrent hypoketotic hypoglycemia, hepatic encephalopathy, progressive cardiomyopathy, and skeletal myopathy, with onset typically in infancy or early childhood. Plasma free carnitine concentrations are profoundly reduced (typically less than 5 micromoles per liter, compared to the normal range of 40 to 60 micromoles per liter). Treatment with oral levocarnitine 50 to 400 mg/kg/day normalizes plasma carnitine, reverses cardiomyopathy, and prevents metabolic crises. Treatment is lifelong and is the FDA-approved primary indication for Carnitor [10, 20].

6.2 Secondary carnitine deficiency and organic acidemias

Secondary carnitine depletion occurs in multiple clinical contexts: end-stage renal disease with hemodialysis, organic acidemias (propionic acidemia, methylmalonic acidemia, isovaleric acidemia), valproic acid therapy, pivalate-containing prodrug therapy, and severe malnutrition. In organic acidemias, accumulating organic acids conjugate with CoA, depleting the mitochondrial CoA pool; L-carnitine supplementation traps these acyl groups as acylcarnitines for renal excretion, restoring free CoA availability and preventing metabolic crisis [9, 27].

6.3 Cardiovascular secondary prevention

The largest and most impactful meta-analysis in the cardiovascular supplementation literature is the DiNicolantonio et al. (2013) systematic review published in Mayo Clinic Proceedings, which pooled 13 controlled trials (N = 3,629) of L-carnitine supplementation in patients following acute myocardial infarction [22]. Results demonstrated:

- All-cause mortality: 27 percent reduction (OR 0.73, 95% CI 0.54 to 0.99, P = 0.05)

- Ventricular arrhythmias: 65 percent reduction (OR 0.35, 95% CI 0.21 to 0.58, $P < 0.0001$)
- Angina development: 40 percent reduction (OR 0.60, 95% CI 0.50 to 0.72, $P < 0.00001$)
- Heart failure development: no significant reduction
- Myocardial reinfarction: no significant reduction

Typical dosing in the included trials was 2 to 6 grams per day orally or 1 to 2 grams intravenously, initiated within 24 hours of acute myocardial infarction and continued for 7 days to 12 months. The mechanism of benefit is attributed to preservation of myocardial carnitine stores (which decline rapidly during ischemia), optimization of fatty acid oxidation in the ischemic border zone, reduction of free radical production, and stabilization of membrane phospholipids [22].

6.4 Chronic heart failure

A 2017 meta-analysis by Song et al. of 17 randomized controlled trials ($N = 1,625$) in chronic heart failure reported that L-carnitine supplementation at 1 to 6 grams per day for 7 days to 3 years, compared to routine treatment, significantly improved left ventricular ejection fraction (+4.14%, 95% CI 2.34 to 5.94%), stroke volume (+8.21 mL, 95% CI 2.31 to 14.11 mL), and cardiac output (+0.88 L/min, 95% CI 0.48 to 1.29 L/min) [33]. However, the analysis did not confirm a significant reduction in all-cause mortality in the chronic heart failure population specifically, distinguishing this population from the acute post-myocardial infarction population in which mortality benefit was demonstrated.

6.5 Hemodialysis-related carnitine deficiency

Hemodialysis patients develop progressive carnitine depletion through dialytic losses (carnitine is freely dialyzable at 161 daltons), reduced renal biosynthetic contribution, and decreased dietary intake. A 2019 Cochrane systematic review assessed L-carnitine supplementation in dialysis populations and reported potential benefits for anemia (reduced erythropoietin requirements), inflammatory markers (significant reduction in C-reactive protein), and intradialytic hypotension, though evidence quality was rated low to moderate and the review concluded that further

well-designed trials were needed to confirm efficacy and optimize dosing [34]. Typical dosing in dialysis studies is 10 to 20 mg/kg intravenously at the end of each dialysis session, or 1 to 2 grams orally daily.

6.6 Exercise performance

Multiple systematic reviews and meta-analyses have assessed L-carnitine supplementation for exercise performance in healthy populations. A 2021 systematic review and meta-analysis from the rehabilitation perspective reported that L-carnitine supplementation significantly increased maximal oxygen consumption (VO₂max) and reduced blood lactate concentrations after exercise [35]. A 2021 systematic review on the effects of acute and chronic oral L-carnitine supplementation on exercise performance reported that supplementation with 3 to 4 grams of L-carnitine or glycine propionyl-L-carnitine ingested 60 to 90 minutes before exercise, as well as doses of 2 to 2.72 grams with carbohydrates over periods of 9 to 24 weeks, improved performance in incremental tests, sprint tests, Wingate tests, and all-out tests [36]. A meta-analysis of the effects on exercise-induced muscle damage reported reduced markers of muscle damage (creatine kinase, lactate dehydrogenase) and reduced muscle soreness with supplementation [37]. The carbohydrate co-ingestion strategy, based on the Wall et al. (2011) demonstration that insulin stimulation is required to drive L-carnitine uptake into skeletal muscle via OCTN2, has become a standard protocol in exercise research [38].

6.7 Male reproductive health

L-Carnitine and acetyl-L-carnitine are present at high concentrations in the epididymis and seminal fluid, where carnitine supports sperm maturation, motility, and energy metabolism. A systematic review of randomized controlled trials reported that carnitine supplementation significantly improved total sperm motility, progressive sperm motility, and sperm morphology in men with idiopathic infertility [39]. In a network meta-analysis across multiple antioxidant interventions, L-carnitine was ranked first for improvements in sperm motility and sperm morphology [40]. However, improvements in sperm parameters have not consistently translated to significant improvements in pregnancy rates in the available randomized trials, and the evidence base consists of a limited number of trials with high heterogeneity [39]. Typical dosing is 1 to 3 grams per day of L-carnitine and/or 0.5 to 2 grams per day of acetyl-L-carnitine for 3 to 6 months.

6.8 Diabetic peripheral neuropathy

Acetyl-L-carnitine (ALCAR), the acetylated ester of L-carnitine, has been the subject of randomized controlled trials for diabetic peripheral neuropathy. A Cochrane review and a systematic review with meta-analysis reported that ALCAR significantly reduced pain scores in patients with peripheral neuropathy and appeared more effective in diabetic neuropathy than in neuropathy of other etiologies [41, 42]. The mechanism involves ALCAR-mediated support of nerve cell energy metabolism, promotion of nerve growth factor activity, and facilitation of nerve fiber regeneration. Typical dosing in neuropathy trials is 1.5 to 3 grams per day of acetyl-L-carnitine for 6 to 12 months.

6.9 Cognitive decline and Alzheimer's disease

Acetyl-L-carnitine has been studied for age-related cognitive decline and Alzheimer's disease, based on its role in cholinergic neurotransmission (acetylcar-nitine serves as an acetyl group donor for acetylcholine synthesis) and mitochondrial energy metabolism in neurons. Meta-analyses have reported modest short-term benefits on cognitive test scores (Mini Mental State Examination improvement at 24 weeks) but no sustained benefit at 52 weeks [43]. The routine clinical use of acetyl-L-carnitine for dementia is not supported by current evidence, though the compound remains under investigation as a component of multimodal neuropro- tective strategies.

6.10 Cancer-related fatigue

L-Carnitine deficiency has been documented in cancer patients, attributed to re- duced dietary intake, catabolic metabolism, and drug-induced depletion. Several small randomized controlled trials have reported improvements in fatigue scores with L-carnitine supplementation at 1 to 4 grams per day in patients with advanced cancer or cancer-treatment-related fatigue, though larger confirmatory trials have produced mixed results [44]. The evidence is insufficient to support routine supple- mentation for cancer-related fatigue, but carnitine status assessment and repletion in deficient cancer patients is a reasonable clinical approach.

6.11 Type 2 diabetes and metabolic syndrome

L-Carnitine supplementation has been investigated for glycemic control and lipid profiles in type 2 diabetes and metabolic syndrome. A systematic review reported modest improvements in fasting glucose, HbA1c, total cholesterol, and LDL cholesterol with L-carnitine supplementation, attributed to improved mitochondrial fatty acid oxidation and reduced lipotoxicity [45]. Effect sizes are small and clinical significance uncertain; L-carnitine is not established as a primary intervention for glycemic control.

7. Reported Research Dose Ranges

7.1 Pharmaceutical doses (FDA-approved indications)

Primary carnitine deficiency (oral): Adults, 990 mg (three 330 mg tablets) two to three times daily; children, 50 to 100 mg/kg/day in divided doses, maximum 3 grams per day. Dosage adjusted based on clinical response and plasma carnitine concentrations [10].

Hemodialysis-associated carnitine deficiency (intravenous): 10 to 20 mg/kg dry body weight administered as a slow intravenous bolus (over 2 to 3 minutes) at the end of each hemodialysis session. Typical starting dose is 10 mg/kg (approximately 700 mg for a 70-kilogram patient) [10].

7.2 Supplemental and investigational doses

Cardiovascular secondary prevention: 2 to 6 grams per day orally, initiated within 24 hours of acute myocardial infarction and continued for weeks to months [22].

Chronic heart failure: 1 to 6 grams per day orally, chronic administration [33].

Exercise performance: 1 to 4 grams per day orally; acute protocols (single dose 60 to 90 minutes pre-exercise) at 3 to 4 grams; chronic protocols at 1 to 2.72 grams per day with carbohydrate co-ingestion (80 grams carbohydrate twice daily to stimulate insulin-driven muscle uptake) for 9 to 24 weeks [36, 38].

Male fertility: 1 to 3 grams per day of L-carnitine and/or 0.5 to 2 grams per day of acetyl-L-carnitine for 3 to 6 months [39].

Diabetic neuropathy (ALCAR): 1.5 to 3 grams per day of acetyl-L-carnitine for 6 to 12 months [41].

Cognitive support (ALCAR): 1 to 3 grams per day of acetyl-L-carnitine [43].

Cancer-related fatigue: 1 to 4 grams per day orally [44].

8. Sourcing and Quality Verification

Pharmaceutical-grade levocarnitine (Carnitor, Lediand Biosciences) is the highest-quality source for clinical research applications where regulatory equivalence is required. Generic levocarnitine preparations are available in multiple jurisdictions.

Nutraceutical-grade L-carnitine is manufactured by several major producers, with Lonza (Carnipure brand) being the dominant supplier of fermentation-derived L-carnitine to the global supplement industry. Carnipure-certified products carry a quality mark indicating manufacture by Lonza from a guaranteed pure L-carnitine source with less than 0.1 percent D-carnitine contamination. Other major suppliers include Sigma-Aldrich, NOW Foods, and numerous Chinese and Indian API manufacturers.

Available forms include L-carnitine free base, L-carnitine hydrochloride, L-carnitine L-tartrate (preferred for supplement formulation owing to improved stability and flowability), acetyl-L-carnitine hydrochloride, propionyl-L-carnitine hydrochloride, and glycine propionyl-L-carnitine hydrochloride.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography or capillary electrophoresis purity assessment (target: greater than 99 percent for pharmaceutical grade, greater than 98 percent for research grade)
- Chiral purity assessment by chiral HPLC or polarimetry to confirm absence of D-carnitine contamination (target: greater than 99.5 percent L-enantiomer). D-Carnitine contamination is a specific concern in chemically synthesized L-carnitine; fermentation-derived material (Lonza Carnipure) produces exclusively the L-enantiomer
- Mass spectrometric confirmation of molecular identity ($[M+H]^+ = 162.11$)
- Residual solvent analysis by gas chromatography
- Heavy metals analysis (arsenic, cadmium, lead, mercury) per USP or ICH guidelines
- Microbial limits testing for oral preparations

Third-party analytical confirmation of vendor certificates of analysis is appropriate for any investigation where dose-response precision is required. The L-carnitine supplement market is large and competitive, and product quality varies; independent testing organizations (NSF International, USP Dietary Supplement Verification, ConsumerLab, Informed Sport) provide certification services.

9. Reconstitution and Handling

L-Carnitine (free base and salts) is freely soluble in water at room temperature. The compound is supplied as a white crystalline powder (free base or tartrate salt) or as a pre-formulated oral solution (Carnitor, 100 mg/mL) or intravenous solution (Carnitor injection, 200 mg/mL).

For research applications, stock solutions are typically prepared at 100 to 500 mg/mL in purified water, phosphate-buffered saline, or cell culture medium. The compound is stable in aqueous solution at pH 3 to 8 and at temperatures up to 40 degrees Celsius. Solutions should be sterile-filtered (0.22 micrometer) for cell culture or in vivo applications.

Storage of the solid compound should be at room temperature (15 to 30 degrees Celsius) in a tightly sealed container protected from moisture (the compound is hygroscopic). Aqueous stock solutions are stable at refrigerated conditions (2 to 8 degrees Celsius) for at least 30 days and at room temperature for at least 14 days. Long-term storage of stock solutions is acceptable at -20 degrees Celsius; the compound tolerates repeated freeze-thaw cycles without significant degradation.

Pharmaceutical levocarnitine injection (Carnitor) is a preservative-free aqueous solution that should be used within 24 hours of opening the vial; any unused portion should be discarded. The injection is compatible with 0.9 percent sodium chloride for intravenous dilution.

L-Carnitine L-tartrate is the preferred salt form for solid supplement formulations owing to its lower hygroscopicity, improved flowability, and stability compared to the free base. The hydrochloride salt is preferred for analytical reference standards and for applications requiring defined stoichiometry.

10. Stack Interaction Considerations

L-Carnitine interacts with several compound classes through pharmacokinetic and pharmacodynamic mechanisms. Investigators and practitioners should consider the following:

Insulin and carbohydrates: Insulin stimulates OCTN2-mediated uptake of L-carnitine into skeletal muscle. The Wall et al. (2011) study demonstrated that co-ingestion of L-carnitine with a high-carbohydrate meal (80 grams carbohydrate) significantly increased muscle carnitine content over 24 weeks, whereas L-carnitine alone did not [38]. This interaction is exploited in exercise performance research protocols and is relevant for any application seeking to increase tissue carnitine stores.

Valproic acid: Valproic acid depletes carnitine through conjugation of the valproyl moiety with CoA (reducing free CoA) and through inhibition of carnitine biosynthesis and renal reabsorption. L-Carnitine supplementation (50 to 100 mg/kg/day) is standard adjunctive therapy for valproic acid-induced hyperammonemia and is recommended in valproic acid overdose [27].

Warfarin and other vitamin K antagonists: Case reports have described potentiation of warfarin anticoagulation by L-carnitine, though the mechanism is unclear and the interaction is not well characterized in controlled studies. INR monitoring is recommended when L-carnitine is added to warfarin therapy.

Thyroid hormones: L-Carnitine has been reported to inhibit both triiodothyronine (T3) and thyroxine (T4) entry into cell nuclei in vitro. A randomized controlled trial reported that L-carnitine at 2 to 4 grams per day ameliorated symptoms of hyperthyroidism and reduced thyroid hormone action [46]. The interaction is potentially beneficial in hyperthyroidism but should be considered a caution in hypothyroidism.

Coenzyme Q10 (CoQ10): The combination of L-carnitine and CoQ10 is commonly used in cardiovascular and mitochondrial support protocols. The rationale is complementary: L-carnitine facilitates fatty acid delivery to the mitochondrial matrix for beta-oxidation, while CoQ10 serves as an electron carrier in the electron trans-

port chain. Small clinical trials have reported additive benefits on cardiac function and exercise tolerance, though large randomized trials of the combination are lacking.

Alpha-lipoic acid: The combination of L-carnitine (or acetyl-L-carnitine) with alpha-lipoic acid has been studied for neuroprotection and metabolic support, with complementary mechanisms (carnitine for fatty acid oxidation, lipoic acid for pyruvate dehydrogenase cofactor activity and antioxidant recycling). Preclinical evidence supports additive or synergistic neuroprotective effects; clinical evidence is limited.

D-Carnitine: D-Carnitine (the non-physiological enantiomer) competitively inhibits OCTN2-mediated uptake of L-carnitine and should never be co-administered. Racemic DL-carnitine is contraindicated for this reason [3].

Pivalate-containing drugs: Pivampicillin, pivmecillinam, and other pivalate-containing prodrugs release pivalic acid upon hydrolysis; pivalic acid is conjugated with carnitine and excreted as pivaloylcarnitine, producing secondary carnitine depletion. L-Carnitine supplementation may be indicated during chronic pivalate prodrug therapy.

11. Adverse Events and Safety

11.1 Common adverse events

L-Carnitine is well tolerated at doses up to 3 grams per day in most individuals. The principal adverse events are gastrointestinal:

- Nausea and vomiting (dose-dependent, more common at doses above 3 grams per day)
- Abdominal cramps and diarrhea (dose-dependent)
- Fishy body odor (resulting from the excretion of trimethylamine, a gut microbial metabolite of unabsorbed carnitine; more pronounced at higher doses and in individuals with greater TMA-producing microbial populations)

These adverse events are generally mild, dose-dependent, and manageable with dose reduction or division of the daily dose into smaller portions.

11.2 TMAO-mediated cardiovascular risk

The most significant safety concern for chronic L-carnitine supplementation is the gut microbial production of trimethylamine (TMA) from unabsorbed carnitine, with subsequent hepatic oxidation to trimethylamine N-oxide (TMAO) [11, 12]. The Koeth et al. (2013) study in *Nature Medicine* demonstrated that:

- Intestinal microbiota from omnivorous humans metabolize L-carnitine to TMA and TMAO at substantially higher rates than microbiota from vegetarians or vegans
- Chronic L-carnitine feeding in mice accelerated atherosclerosis in a microbiota-dependent manner
- Plasma TMAO concentrations are independently associated with major adverse cardiovascular events in human observational cohorts

Subsequent studies have confirmed the TMAO-cardiovascular risk association in large prospective cohorts, with hazard ratios across TMAO quintiles of approximately 1.02, 1.17, 1.23, and 1.33 compared to the lowest quintile [47]. The pathway is modifiable: antibiotic suppression of gut microbiota eliminates TMAO production;

dietary modification (reduced red meat, increased fiber, polyphenol-rich foods) modulates the microbiome toward lower TMA production; and specific probiotic strains have been shown to reduce TMAO production in preclinical models [48].

The clinical significance of the TMAO pathway for L-carnitine supplementation remains a subject of debate. The DiNicolantonio et al. (2013) meta-analysis demonstrated cardiovascular mortality benefit from L-carnitine in post-myocardial infarction patients despite the TMAO concern, suggesting that the direct metabolic benefits of carnitine in the ischemic myocardium may outweigh the indirect TMAO-mediated risk in this population. Dose, duration, and individual microbiome composition are likely determinants of the net cardiovascular effect.

11.3 D-Carnitine contamination

Products containing D-carnitine (the non-physiological enantiomer) or racemic DL-carnitine can produce symptoms of L-carnitine deficiency through competitive inhibition of OCTN2-mediated L-carnitine transport. D-Carnitine contamination is a specific quality concern in chemically synthesized carnitine; fermentation-derived products (Lonza Carnipure) do not contain D-carnitine. Enantiomeric purity verification is important for any L-carnitine product [3].

11.4 Drug interactions of safety concern

The interaction with warfarin (potential potentiation of anticoagulation) and the interaction with thyroid hormones (potential inhibition of thyroid hormone nuclear entry) are the principal pharmacodynamic safety considerations. See Section 10 for details.

11.5 Seizures

A potential concern relates to reports of seizure occurrence in some individuals with pre-existing seizure disorders who received L-carnitine, though a causal relationship has not been established in controlled studies. Patients with epilepsy should be monitored if L-carnitine supplementation is initiated.

11.6 Pregnancy and lactation

L-Carnitine is present in breast milk and crosses the placenta. No teratogenic effects have been reported in animal studies at multiples of the human dose. Human pregnancy safety data are limited. Supplementation during pregnancy should be based on clinical need, with monitoring of maternal and fetal well-being.

11.7 Upper intake considerations

No formal Tolerable Upper Intake Level (UL) has been established by the Institute of Medicine or the European Food Safety Authority. Doses up to 3 grams per day are generally well tolerated; the Linus Pauling Institute and other advisory bodies note that doses above 3 grams per day increase the incidence of gastrointestinal adverse effects and fishy body odor. Long-term safety data at doses above 3 grams per day are limited.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five mitochondrial bioenergetic and metabolic support compounds against L-carnitine, evaluated against five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile, and overall validation. The five compounds were selected as the principal agents with substantive clinical or pre-clinical pharmacology in overlapping therapeutic domains (cardiovascular support, exercise performance, metabolic optimization, neuroprotection).

12.1 Acetyl-L-Carnitine (ALCAR)

Mechanism: Acetylated ester of L-carnitine. Serves as both an L-carnitine prodrug (releasing free carnitine and acetyl-CoA upon hydrolysis) and as a direct-acting metabolic intermediate. Provides acetyl groups for acetylcholine synthesis in cholinergic neurons, supports mitochondrial energy metabolism, and crosses the blood-brain barrier more efficiently than free L-carnitine [31]. The acetyl moiety provides additional metabolic activity beyond the parent compound.

Clinical trajectory: ALCAR has been studied extensively in diabetic peripheral neuropathy, age-related cognitive decline, Alzheimer's disease, depression, and HIV-associated neuropathy. A Cochrane review of ALCAR for diabetic neuropathy reported significant pain reduction [41]. Meta-analyses of ALCAR for cognitive decline have reported modest short-term benefits [43]. The compound is available as a dietary supplement globally and is not subject to prescription requirements in most jurisdictions.

Novelty: Low. ALCAR is a naturally occurring physiological ester of L-carnitine and has been studied since the 1980s. The mechanism is well established and is an extension of L-carnitine biochemistry.

Effect size: Moderate in neuropathy (significant pain reduction compared to placebo); modest in cognitive decline (short-term MMSE improvement without sustained benefit); modest in depression (small controlled trials with positive signals). The neuropathy effect is the most consistently replicated [41, 42].

Promising potential: Moderate. The neuropathy and neuroprotection applications have the strongest clinical support. The compound is limited by the same TMAO concern as L-carnitine at high doses, though the acetyl group may slightly modify gut microbial metabolism.

Side-effect profile: Similar to L-carnitine (gastrointestinal symptoms, fishy odor at high doses). Some reports of increased agitation or insomnia in elderly patients, attributed to the cholinergic activity.

Overall validation: Moderate to high. Substantial clinical trial database, Cochrane review support for neuropathy, multiple meta-analyses across indications. The most clinically validated L-carnitine derivative.

Comparison to L-carnitine: ALCAR is best understood as a specialized derivative rather than an alternative. It shares all of L-carnitine's mitochondrial transport functions and adds the acetyl group delivery for cholinergic and energetic support. For neuropathy and central nervous system applications, ALCAR is preferred owing to superior blood-brain barrier penetration. For cardiovascular and general metabolic applications, free L-carnitine remains the standard form.

12.2 Coenzyme Q10 (Ubiquinone/Ubiquinol)

Mechanism: Coenzyme Q10 is a lipophilic benzoquinone that functions as an essential electron carrier in the mitochondrial electron transport chain (complexes I to III) and as a lipid-soluble antioxidant in cell membranes and lipoproteins [49]. The mechanism is complementary to L-carnitine: L-carnitine delivers fatty acid substrates to the mitochondrial matrix for beta-oxidation, while CoQ10 carries the resulting electrons through the respiratory chain to drive ATP synthesis.

Clinical trajectory: CoQ10 has been studied extensively in heart failure, statin-associated myopathy, hypertension, Parkinson's disease, and migraine prevention. The Q-SYMBIO trial (2014), a multicenter randomized controlled trial in 420 chronic heart failure patients, reported significant reductions in major adverse cardiovascular events (hazard ratio 0.50), cardiovascular mortality, and all-cause mortality with CoQ10 supplementation at 300 mg per day for 2 years [50]. The trial represented the strongest evidence for a mitochondrial supplement in a cardiovascular outcome trial.

Novelty: Low. CoQ10 has been studied since the 1960s and is among the most extensively characterized mitochondrial supplements.

Effect size: Moderate to large in the Q-SYMBIO heart failure trial (50 percent reduction in MACE); small to moderate in statin-associated myopathy meta-analyses; small in hypertension meta-analyses. The heart failure effect size exceeds that reported for L-carnitine in the Song et al. (2017) heart failure meta-analysis.

Promising potential: Moderate. The Q-SYMBIO result is the strongest positive cardiovascular outcome trial for any mitochondrial supplement, but has not been replicated in an independent large-scale trial. Ongoing research in heart failure, neurodegenerative disease, and mitochondrial disorders.

Side-effect profile: Excellent. CoQ10 is well tolerated at doses up to 1,200 mg per day. Adverse events are rare and generally limited to mild gastrointestinal symptoms. No TMAO pathway concern.

Overall validation: High. Extensive preclinical and clinical database, positive cardiovascular outcome trial, established safety profile.

Comparison to L-carnitine: CoQ10 and L-carnitine operate at different steps in the same mitochondrial energy production pathway and are frequently combined in cardiovascular and mitochondrial support protocols. CoQ10 has the advantage of a positive large-scale cardiovascular outcome trial (Q-SYMBIO) and the absence of the TMAO safety concern. L-Carnitine has the advantage of FDA-approved pharmaceutical indications, broader clinical evidence across multiple therapeutic domains, and lower cost.

12.3 Alpha-Lipoic Acid (ALA, Thiocetic Acid)

Mechanism: Alpha-lipoic acid is a dithiol compound that functions as a cofactor for mitochondrial alpha-keto acid dehydrogenase complexes (pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, branched-chain alpha-keto acid dehydrogenase) and as a potent redox-active antioxidant capable of recycling other antioxidants (glutathione, vitamin C, vitamin E) [51]. The mechanism overlaps with L-carnitine at the level of mitochondrial substrate flux: L-carnitine delivers fatty acids for beta-oxidation, while ALA facilitates the oxidative decarboxylation of pyruvate and alpha-ketoglutarate that links glycolysis and the tricarboxylic acid cycle.

Clinical trajectory: ALA has been studied extensively for diabetic peripheral neuropathy. The SYDNEY-2 trial and other randomized controlled trials have demonstrated significant pain reduction and nerve conduction velocity improvement with intravenous ALA at 600 mg per day [52]. Oral ALA at 600 to 1,800 mg per

day has been studied for glycemic control, weight management, and neuroprotection. ALA is approved as a pharmaceutical for diabetic neuropathy in Germany and other European jurisdictions.

Novelty: Low. ALA has been studied since the 1950s and is well characterized.

Effect size: Moderate in diabetic neuropathy (significant symptom reduction; effect sizes comparable to ALCAR in neuropathy trials); small in glycemic control; small in weight management.

Promising potential: Moderate. Established pharmaceutical indication in European jurisdictions for diabetic neuropathy. Ongoing research in neurodegenerative disease and metabolic syndrome.

Side-effect profile: Good. Generally well tolerated. Dose-dependent gastrointestinal symptoms (nausea, abdominal discomfort) at higher oral doses. Rare reports of insulin autoimmune syndrome in genetically predisposed individuals. No TMAO pathway concern.

Overall validation: High for diabetic neuropathy (multiple RCTs, pharmaceutical approval in some jurisdictions); moderate for other indications.

Comparison to L-carnitine: ALA and L-carnitine (as ALCAR) have overlapping clinical evidence in diabetic neuropathy with comparable effect sizes. The compounds act at different mitochondrial targets and have been studied in combination with evidence of additive neuroprotective effects in preclinical models. For neuropathy, both are reasonable candidates; ALA has the advantage of pharmaceutical regulatory approval for this indication in some jurisdictions, while ALCAR has broader evidence across neuropathy subtypes.

12.4 D-Ribose

Mechanism: D-Ribose is a naturally occurring pentose sugar that serves as the sugar backbone of ATP, ADP, AMP, NAD, NADH, FAD, FADH₂, and coenzyme A. Supplemental D-ribose is proposed to accelerate the de novo synthesis of purine nucleotides (the adenine nucleotide salvage and de novo pathways) in tissues with high energy demand, particularly post-ischemic myocardium and exercising skeletal muscle, where ATP depletion exceeds the rate of nucleotide resynthesis [53].

Clinical trajectory: Small clinical trials have studied D-ribose for chronic heart failure, exercise performance, fibromyalgia, and chronic fatigue syndrome. A pilot study in 41 heart failure patients reported improved diastolic function and quality of life scores with D-ribose at 5 grams three times daily for 6 weeks [53]. Exercise performance trials have produced mixed results. The evidence base is substantially smaller and less mature than that of L-carnitine.

Novelty: Low. The biochemistry is well established; the clinical application as a supplement is straightforward.

Effect size: Small to moderate in pilot heart failure studies; inconsistent in exercise performance. No large-scale cardiovascular outcome data.

Promising potential: Low to moderate. The small evidence base and absence of large-scale trials limit the clinical trajectory. The compound is of theoretical interest for ATP depletion syndromes but lacks the clinical validation of L-carnitine or CoQ10.

Side-effect profile: Generally well tolerated. Hypoglycemia is a potential concern in diabetic patients (D-ribose is a reducing sugar). Gastrointestinal symptoms at higher doses. No TMAO pathway concern.

Overall validation: Low. Limited clinical trial evidence, no large-scale randomized trials, no pharmaceutical regulatory approval.

Comparison to L-carnitine: D-Ribose addresses a different aspect of mitochondrial bioenergetics (nucleotide pool replenishment rather than substrate delivery for beta-oxidation) and is substantially less clinically validated than L-carnitine. The combination of D-ribose with L-carnitine and CoQ10 has been proposed as a comprehensive mitochondrial support strategy but has not been studied in rigorous clinical trials.

12.5 Propionyl-L-Carnitine (PLC)

Mechanism: Propionyl-L-carnitine is the propionyl ester of L-carnitine. It delivers both L-carnitine (for the fatty acid shuttle) and propionyl-CoA (which enters the tricarboxylic acid cycle via succinyl-CoA through the methylmalonyl-CoA pathway) to tissues. The propionyl moiety is proposed to provide anaplerotic support (replenishment of tricarboxylic acid cycle intermediates) in tissues with high energy demand, particularly cardiac and vascular smooth muscle [54].

Clinical trajectory: PLC has been studied principally for peripheral arterial disease and chronic heart failure. Randomized controlled trials have reported improved walking distance and reduced claudication symptoms in patients with peripheral arterial disease at doses of 1 to 3 grams per day [55]. Small heart failure trials have reported improvements in exercise capacity and ejection fraction. PLC is registered as a pharmaceutical in Italy (Dromos) for peripheral arterial disease.

Novelty: Low. PLC is a naturally occurring L-carnitine ester with well-characterized biochemistry.

Effect size: Moderate in peripheral arterial disease (significant improvement in maximal walking distance in multiple RCTs); small to moderate in heart failure.

Promising potential: Moderate. Pharmaceutical registration in Italy for peripheral arterial disease supports the clinical trajectory. Limited global availability constrains broader clinical adoption.

Side-effect profile: Good. Similar to L-carnitine with respect to gastrointestinal effects. No unique safety concerns beyond those of L-carnitine. TMAO production is expected from unabsorbed material, similar to the parent compound.

Overall validation: Moderate. Pharmaceutical registration for peripheral arterial disease in one jurisdiction; multiple RCTs in peripheral arterial disease and heart failure; smaller evidence base than free L-carnitine.

Comparison to L-carnitine: PLC is a specialized derivative of L-carnitine with a specific niche in peripheral arterial disease. For general mitochondrial support, cardiovascular secondary prevention, exercise performance, and male fertility, free L-carnitine has a broader evidence base and greater availability. For peripheral arterial disease specifically, PLC has stronger evidence than free L-carnitine.

12.6 Comparator summary

The five compounds occupy distinct but overlapping positions in the mitochondrial bioenergetic support landscape. **Acetyl-L-carnitine** is the principal L-carnitine derivative with additional cholinergic and neuroprotective activity, best validated for diabetic peripheral neuropathy. **Coenzyme Q10** operates at a complementary step in mitochondrial energy production and has the strongest cardiovascular outcome trial evidence (Q-SYMBIO) of any compound in this panel. **Alpha-lipoic acid** has the strongest regulatory validation for diabetic neuropathy (pharmaceutical approval

in European jurisdictions) and complementary mitochondrial cofactor activity. **D-Ribose** addresses nucleotide pool replenishment with limited clinical validation. **Propionyl-L-carnitine** is a specialized L-carnitine ester with specific evidence in peripheral arterial disease.

L-Carnitine occupies a central position in this landscape as the physiological substrate of the carnitine shuttle with the broadest clinical evidence base across the largest number of therapeutic domains, the only FDA-approved pharmaceutical indication in its class (primary carnitine deficiency, hemodialysis-related deficiency), and a well-characterized safety profile. Its principal limitation relative to the comparators is the TMAO-mediated cardiovascular risk concern, which is absent for CoQ10, ALA, and D-ribose. The optimal practical approach for mitochondrial and cardiovascular support may involve rational combinations of these compounds, capitalizing on their complementary mechanisms; however, large-scale clinical trials of such combinations are currently lacking.

13. References

1. Vaz FM, Wanders RJ. Carnitine biosynthesis in mammals. *Biochem J*. 2002;361(Pt 3):417-429.
2. Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. *Ann N Y Acad Sci*. 2004;1033:30-41.
3. Pekala J, Patkowska-Sokola B, Bodkowski R, et al. L-carnitine: metabolic functions and meaning in humans life. *Curr Drug Metab*. 2011;12(7):667-678.
4. Strijbis K, Vaz FM, Distel B. Enzymology of the carnitine biosynthesis pathway. *IUBMB Life*. 2010;62(5):357-362.
5. Longo N, Frigeni M, Pasquali M. Carnitine transport and fatty acid oxidation. *Biochim Biophys Acta*. 2016;1863(10):2422-2435.
6. McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system: from concept to molecular analysis. *Eur J Biochem*. 1997;244(1):1-14.
7. Ramsay RR, Gandour RD, van der Leij FR. Molecular enzymology of carnitine transfer and transport. *Biochim Biophys Acta*. 2001;1546(1):21-43.
8. Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q. Role of carnitine in disease. *Nutr Metab (Lond)*. 2010;7:30.
9. Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. *Clin Toxicol (Phila)*. 2009;47(2):101-111.
10. Carnitor (levocarnitine) prescribing information. Leadiant Biosciences, Inc. Gaithersburg, MD. Revised 2018.
11. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. *Nat Med*. 2013;19(5):576-585.
12. Koeth RA, Lam-Galvez BR, Kirsop J, et al. L-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. *J Clin Invest*. 2019;129(1):373-387.

13. Gulewitsch W, Krimberg R. Zur Kenntnis der Extraktivstoffe der Muskeln. II. Mitteilung. Über das Carnitin. Hoppe-Seylers Z Physiol Chem. 1905;45:326-330.
14. Tomita M, Sendju Y. Über die Oxyaminverbindungen, welche die Biuretreaktion zeigen. III. Spaltung der gamma-amino-beta-hydroxy-buttersäure in die optisch aktiven Komponenten. Hoppe-Seylers Z Physiol Chem. 1927;169:263-277.
15. Fraenkel G. The distribution of vitamin BT (carnitine) throughout the animal kingdom. Arch Biochem Biophys. 1954;50(2):486-495.
16. Carter HE, Bhattacharyya PK, Weidman KR, Fraenkel G. Chemical studies on vitamin BT: isolation and characterization as carnitine. Arch Biochem Biophys. 1952;38:405-416.
17. Fritz IB. The effects of muscle extracts on the oxidation of palmitic acid by liver slices and homogenates. Acta Physiol Scand. 1955;34:367-385.
18. McGarry JD, Mannaerts GP, Foster DW. A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J Clin Invest. 1977;60(1):265-270.
19. Engel AG, Angelini C. Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science. 1973;179(4076):899-902.
20. Nezu J, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet. 1999;21(1):91-94.
21. Ahmad S. L-carnitine in dialysis patients. Semin Dial. 2001;14(3):209-217.
22. DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc. 2013;88(6):544-551.
23. Indiveri C, Iacobazzi V, Tonazzi A, et al. The mitochondrial carnitine/acylcarnitine carrier: function, structure and physiopathology. Mol Aspects Med. 2011;32(4-6):223-233.
24. Bonnefont JP, Djouadi F, Prip-Buus C, et al. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med. 2004;25(5-6):495-520.

25. Muoio DM, Noland RC, Kovalik JP, et al. Muscle-specific deletion of carnitine acetyltransferase compromises glucose tolerance and metabolic flexibility. *Cell Metab.* 2012;15(5):764-777.
26. Seiler SE, Martin OJ, Noland RC, et al. Obesity and lipotoxicity: role of carnitine acetyltransferase in the metabolic flexibility of skeletal muscle. *Biochem Soc Trans.* 2014;42(3):824-828.
27. Gziut M, MacGregor HJ, Engelman RM, et al. L-carnitine for valproic acid-induced toxicity. *Br J Clin Pharmacol.* 2025;91(2):356-367.
28. Gramignano G, Lusso MR, Madeddu C, et al. Efficacy of L-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. *Nutrition.* 2006;22(2):136-145.
29. Rebouche CJ. Pharmacokinetics of L-carnitine. In: De Simone C, Famularo G, eds. *Carnitine Today*. Landes Bioscience. 1997:99-118.
30. Rebouche CJ, Seim H. Carnitine metabolism and its regulation in microorganisms and mammals. *Annu Rev Nutr.* 1998;18:39-61.
31. Pettegrew JW, Levine J, McClure RJ. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. *Mol Psychiatry.* 2000;5(6):616-632.
32. Malaguarnera M, Cammalleri L, Gargante MP, Vacante M, Colonna V, Motta M. L-carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. *Am J Clin Nutr.* 2007;86(6):1738-1744.
33. Song X, Qu H, Yang Z, Rong J, Cai W, Zhou H. Efficacy and safety of L-carnitine treatment for chronic heart failure: a meta-analysis of randomized controlled trials. *Biomed Res Int.* 2017;2017:6274854.
34. Naini AE, Moradi M, Mortazavi M, et al. Carnitine supplements for people with chronic kidney disease requiring dialysis. *Cochrane Database Syst Rev.* 2019; (12):CD011093.
35. Gnoni A, Longo S, Lecce GP, Giannotti L, Gnoni GV, Giannotti L. Clinical effects of L-carnitine supplementation on physical performance in healthy subjects, the key to success in rehabilitation: a systematic review and meta-analysis

- from the rehabilitation point of view. *J Funct Morphol Kinesiol*. 2021;6(4):93.
36. Yarizadeh H, Shab-Bidar S, Zamani B, Vanani AN, Baharloo H, Djafarian K. Effect of acute and chronic oral L-carnitine supplementation on exercise performance based on the exercise intensity: a systematic review. *Nutrients*. 2021;14(1):106.
37. Chen Y, Cao M, Yang M, et al. Effects of L-carnitine supplementation on markers of exercise-induced muscle damage in healthy adults: a systematic review and meta-analysis of randomized controlled trials. *J Exerc Sci Fit*. 2025;23(2):100-109.
38. Wall BT, Stephens FB, Constantin-Teodosiu D, Marimuthu K, Macdonald IA, Greenhaff PL. Chronic oral ingestion of L-carnitine and carbohydrate increases muscle carnitine content and alters muscle fuel metabolism during exercise in humans. *J Physiol*. 2011;589(Pt 4):963-973.
39. Salas-Huetos A, Rosique-Esteban N, Becerra-Tomas N, Vizmanos B, Bullo M, Salas-Salvado J. L-carnitine and L-acetylcarnitine supplementation for idiopathic male infertility. *Reprod Fertil*. 2020;1(1):67-81.
40. Zhou B, Zhang X, Li N, et al. The effect of antioxidants on sperm quality parameters and pregnancy rates for idiopathic male infertility: a network meta-analysis of randomized controlled trials. *Front Endocrinol (Lausanne)*. 2022;13:810242.
41. Rolim LCSP, Martins JR, Rodrigues PP, et al. Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy. *Cochrane Database Syst Rev*. 2019; (6):CD011265.
42. Li S, Li Q, Li Y, Li L, Tian H, Sun X. Acetyl-L-carnitine in the treatment of peripheral neuropathic pain: a systematic review and meta-analysis of randomized controlled trials. *PLoS One*. 2015;10(3):e0119479.
43. Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. *Int Clin Psychopharmacol*. 2003;18(2):61-71.
44. Cruciani RA, Dvorkin E, Homel P, et al. L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. *J Pain Symptom Manage*. 2009;37(4):622-631.

45. Bene J, Hadzsiev K, Melegh B. Role of carnitine and its derivatives in the development and management of type 2 diabetes. *Nutr Diabetes*. 2018;8(1):8.
46. Benvenaga S, Ruggeri RM, Russo A, Lapa D, Campenni A, Trimarchi F. Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial. *J Clin Endocrinol Metab*. 2001;86(8):3579-3594.
47. Heianza Y, Ma W, Manson JE, Rexrode KM, Qi L. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and meta-analysis of prospective studies. *J Am Heart Assoc*. 2017;6(7):e004947.
48. Rath S, Heidrich B, Pieper DH, Gammerman A. Uncovering the trimethylamine-producing bacteria of the human gut microbiota. *Microbiome*. 2017;5(1):54.
49. Littarru GP, Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. *Mol Biotechnol*. 2007;37(1):31-37.
50. Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO, a randomized double-blind trial. *JACC Heart Fail*. 2014;2(6):641-649.
51. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. *Biochim Biophys Acta*. 2009;1790(10):1149-1160.
52. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. *Diabetes Care*. 2006;29(11):2365-2370.
53. Omran H, Illien S, MacCarter D, St Cyr J, Luderitz B. D-Ribose improves diastolic function and quality of life in congestive heart failure patients: a prospective feasibility study. *Eur J Heart Fail*. 2003;5(5):615-619.
54. Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. *Ann N Y Acad Sci*. 2004;1033:79-91.

55. Hiatt WR, Regensteiner JG, Creager MA, et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. *Am J Med.* 2001;110(8):616-622.
-

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. L-Carnitine (levocarnitine) is approved by the United States Food and Drug Administration for the treatment of primary systemic carnitine deficiency and for carnitine deficiency in end-stage renal disease patients on hemodialysis. Supplemental L-carnitine is marketed as a dietary supplement and is not subject to premarket FDA approval for supplemental indications. Investigators should consult their local regulatory authority before any human research application.